COR Earnings Date: Nov 4, 2026 (Estimated) — Cencora, Inc.
NYSE · Healthcare · Medical Distribution
Updated
When is COR's next earnings date?
Cencora, Inc. (COR) is expected to report Q4 2026 earnings on Wednesday, November 4, 2026 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $4.58 on revenue of $87.95B.
How did COR do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q3 2026), Cencora, Inc. posted EPS of $4.48 versus the $4.35 estimate, a beat of 2.8%. Revenue was $84.75B against a $84.31B estimate. The stock's 1-day post-earnings move was +3.6%.
How much does COR stock move after earnings?
COR beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.5% (up or down) in the day after earnings.
About Cencora, Inc.
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q3 2026 | 4.35 | 4.48 | +2.75% | $84.75B | ✅ Beat | +3.57% | +9.01% | +10.03% |
| 2026-05-06 | Q2 2026 | 4.74 | 4.75 | +0.21% | $78.36B | ✅ Beat | -17.38% | -14.70% | -11.43% |
| 2026-02-04 | Q1 2026 | 4.05 | 4.08 | +0.74% | $85.93B | ✅ Beat | -8.78% | -0.48% | -0.51% |
| 2025-11-05 | Q4 2025 | 3.79 | 3.84 | +1.32% | $83.73B | ✅ Beat | +2.75% | +5.97% | -1.84% |
| 2025-08-06 | Q3 2025 | 3.81 | 4.00 | +4.99% | $80.66B | ✅ Beat | -2.93% | -1.09% | +0.31% |
| 2025-02-05 | Q1 2025 | 3.52 | 3.73 | +5.97% | $81.49B | ✅ Beat | +0.68% | -1.91% | +1.10% |
| 2024-11-06 | Q4 2024 | 3.22 | 3.34 | +3.73% | $79.05B | ✅ Beat | +4.87% | +6.33% | +4.65% |
| 2024-07-31 | Q3 2024 | 3.22 | 3.34 | +3.73% | $74.24B | ✅ Beat | +2.96% | +3.80% | +2.56% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q3 FY26 · $84.79B total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| U.S. Healthcare Solutions | 88.3% | $74.86B | — | — | — | — | — |
| International Healthcare Solutions | 9.1% | $7.68B | -1.4% | $7.46B | $7.17B | $7.79B | $7.94B |
| Other | 2.7% | $2.25B | — | — | — | — | — |
By region
Q3 FY26 · $82.54B total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| U.S. Healthcare Solutions | 90.7% | $74.86B | +2.7% | $74.03B | $68.28B | $72.88B | $75.79B |
| International Healthcare Solutions | 9.3% | $7.68B | -1.4% | $7.46B | $7.17B | $7.79B | $7.94B |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.